Boehringer Ingelheim and Berg to Collaborate on Finding Biomarkers for Inflammatory Conditions
Boehringer Ingelheim will use the partnership to reveal novel insights into the complexities of various inflammatory diseases, which opens the potential for a clearer understanding of potential candidate biomarkers.
Berg, a Framingham, MA-based clinical-stage biotechnology company focused on the use of artificial intelligence, and Boehringer Ingelheim announced on May 6, 2020 that they are entering into a collaboration to find candidate biomarkers for inflammatory conditions.
According to a Berg press release, Boehringer Ingelheim will use the partnership to reveal novel insights into the complexities of various inflammatory diseases, which opens the potential for a clearer understanding of potential candidate biomarkers.
“We’re excited to partner with Boehringer Ingelheim, which will combine Boehringer Ingelheim’s translational medicine and biomarker expertise with Berg’s next generation AI-driven, patient-biology capability,” said Dr. Niven R. Narain, Berg co-founder, president, and CEO, in the press release. “Our intent is for Berg’s Interrogative Biology platform to enable the discovery of biomarkers that will revolutionize how to diagnose and treat patients with inflammatory diseases.
Source: Berg
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
